{"id":"NCT01488994","sponsor":"Baxalta now part of Shire","briefTitle":"BAX 326 Pediatric Study","officialTitle":"BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-12-20","primaryCompletion":"2013-05-14","completion":"2013-05-14","firstPosted":"2011-12-09","resultsPosted":"2016-09-01","lastUpdate":"2021-05-20"},"enrollment":23,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia B"],"interventions":[{"type":"BIOLOGICAL","name":"BAX326","otherNames":["BAX 326","RIXUBIS"]}],"arms":[{"label":"BAX326 < 6 years of age","type":"EXPERIMENTAL"},{"label":"BAX326 6 to <12 years of age","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess BAX 326 pharmacokinetic parameters, to evaluate its hemostatic efficacy, safety, immunogenicity, and changes in health-related quality of life in pediatric patients.","primaryOutcome":{"measure":"Adverse Events (AEs) Possibly or Probably Related to BAX326","timeFrame":"Throughout study period (approximately 17 months)","effectByArm":[{"arm":"Pediatric Participants < 6 Years of Age","deltaMin":0,"sd":null},{"arm":"Pediatric Participants 6 to < 12 Years of Age","deltaMin":0,"sd":null},{"arm":"Full Analysis Set","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":11,"countries":["India","Poland","Romania","Russia","Ukraine","United Kingdom"]},"refs":{"pmids":["25495591"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":23},"commonTop":["Immunology test abnormal","Upper respiratory tract infection","Abdominal pain","Toothache","Bronchitis"]}}